|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||




* UMR 7175/CNRS/Universite Strasbourg I, Ecole Supérieure de Biotechnologie de Strasbourg, Illkirch, France,
Institut de Génétique et de Biologie Moléculaire, Illkirch France,
Center of Cardiovascular Medicine, University Wurzburg, Wurzburg, Germany.
L'institut du Thorax, Inserm U533, Nantes, France; and
|| Department of Pharmacology and Toxicology, Kyushu University, Fukuoka, Japan
1Correspondence: UMR 7175/CNRS/Universite Strasbourg I, Ecole Supérieure de Biotechnologie de Strasbourg, Bld. Sébastien Brandt BP. 10413, F-67412 Illkirch, France. E-mail: nebigil{at}esbs.u-strasbg.fr
Prokineticins are potent angiogenic factors that bind to two G protein-coupled receptors to initiate their biological effects. We hypothesize that prokineticin receptor-1 (PKR1/GPR73) signaling may contribute to cardiomyocyte survival or repair in myocardial infarction. Since we showed that prokineticin-2 and PKR1 are expressed in adult mouse heart and cardiac cells, we investigated the role of prokineticin-2 on capillary endothelial cell and cardiomyocyte function. In cultured cardiac endothelial cells, prokineticin-2 or overexpression of PKR1 induces vessel-like formation without increasing VEGF levels. In cardiomyocytes and H9c2 cells, prokineticin-2 or overexpressing PKR1 activates Akt to protect cardiomyocytes against oxidative stress. The survival and angiogenesis promoting effects of prokineticin-2 in cardiac cells were completely reversed by siRNA-PKR1, indicating PKR1 involvement. We thus, further investigated whether intramyocardial gene transfer of DNA encoding PKR1 may rescue the myocardium against myocardial infarction in mouse model. Transient PKR1 gene transfer after coronary ligation reduces mortality and preserves left ventricular function by promoting neovascularization and protecting cardiomyocytes without altering VEGF levels. In human end-stage failing heart samples, reduced PKR1 and prokineticin-2 transcripts and protein levels implicate a more important role for prokineticin-2/PKR1 signaling in heart. Our results suggest that PKR1 may represent a novel therapeutic target to limit myocardial injury following ischemic events.—Urayama, K., Guilini, C., Messaddeq, N., Hu, K., Steenman, M., Kurose, H., Ert, G., Nebigil, C. G. The prokineticin receptor-1 (GPR73) promotes cardiomyocyte survival and angiogenesis
Key Words: PKR1 MI
This article has been cited by other articles:
![]() |
H. Attramadal Prokineticins and the heart: diverging actions elicited by signalling through prokineticin receptor-1 or -2 Cardiovasc Res, January 1, 2009; 81(1): 3 - 4. [Full Text] [PDF] |
||||
![]() |
K. Urayama, D. B. Dedeoglu, C. Guilini, S. Frantz, G. Ertl, N. Messaddeq, and C. G. Nebigil Transgenic myocardial overexpression of prokineticin receptor-2 (GPR73b) induces hypertrophy and capillary vessel leakage Cardiovasc Res, January 1, 2009; 81(1): 28 - 37. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. C. Denison, S. Battersby, A. E. King, M. Szuber, and H. N. Jabbour Prokineticin-1: A Novel Mediator of the Inflammatory Response in Third-Trimester Human Placenta Endocrinology, July 1, 2008; 149(7): 3470 - 3477. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Urayama, C. Guilini, G. Turkeri, S. Takir, H. Kurose, N. Messaddeq, A. Dierich, and C. G. Nebigil Prokineticin Receptor-1 Induces Neovascularization and Epicardial-Derived Progenitor Cell Differentiation Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 841 - 849. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |